Search Results - Manyak, Erika

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors

    Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors by Fan, Bin, Mellinghoff, Ingo K., Wen, Patrick Y., Lowery, Maeve A., Goyal, Lipika, Tap, William D., Pandya, Shuchi S., Manyak, Erika, Jiang, Liewen, Liu, Guowen, Nimkar, Tara, Gliser, Camelia, Prahl Judge, Molly, Agresta, Sam, Yang, Hua, Dai, David

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Discovery of Efficacious Pseudomonas aeruginosa-Targeted Siderophore-Conjugated Monocarbams by Application of a Semi-mechanistic Pharmacokinetic/Pharmacodynamic Model

    Discovery of Efficacious Pseudomonas aeruginosa-Targeted Siderophore-Conjugated Monocarbams by Application of a Semi-mechanistic Pharmacokinetic/Pharmacodynamic Model by Murphy-Benenato, Kerry E, Bhagunde, Pratik R, Chen, April, Davis, Hajnalka E, Durand-Réville, Thomas F, Ehmann, David E, Galullo, Vincent, Harris, Jennifer J, Hatoum-Mokdad, Holia, Jahić, Haris, Kim, Aryun, Manjunatha, M. R, Manyak, Erika L, Mueller, John, Patey, Sara, Quiroga, Olga, Rooney, Michael, Sha, Li, Shapiro, Adam B, Sylvester, Mark, Tan, Beesan, Tsai, Andy S, Uria-Nickelsen, Maria, Wu, Ye, Zambrowski, Mark, Zhao, Shannon X

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors

    866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors by Kuplast-Barr, Kristy, Johnson, Melissa, Patel, Manish, Yap, Timothy, Falchook, Gerald, LoRusso, Patricia, Abo, Ryan, Liu, Chang, Manyak, Erika, Cleary, Lisa, Bozon, Viviana, Parasuraman, Sudha, Keilhack, Heike, McEachern, Kristen

    Request full text
    Article
    Save to List
    Saved in:
  4. 4
    SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3

    SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3 by Murphy-Benenato, Kerry E, Dangel, Brian, Davis, Hajnalka E, Durand-Réville, Thomas F, Ferguson, Andrew D, Gao, Ning, Jahić, Haris, Mueller, John P, Manyak, Erika L, Quiroga, Olga, Rooney, Michael, Sha, Li, Sylvester, Mark, Wu, Frank, Zambrowski, Mark, Zhao, Shannon X

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections

    First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections by Talley, Angela K, Thurston, Archie, Moore, Grayson, Gupta, Vipul K, Satterfield, Myriah, Manyak, Erika, Stokes, Suzanne, Dane, Aaron, Melnick, David

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

    Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects by Eckburg, Paul B, Jain, Akash, Walpole, Susannah, Moore, Grayson, Utley, Luke, Manyak, Erika, Dane, Aaron, Melnick, David

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Tebipenem Pivoxil Hydrobromide on QT/QTc Intervals in Healthy Subjects

    Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Tebipenem Pivoxil Hydrobromide on QT/QTc Intervals in Healthy Subjects by Gupta, Vipul K, Maier, Gary, Eckburg, Paul, Morelli, Lisa, Lei, Yang, Jain, Akash, Manyak, Erika, Melnick, David

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies

    Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies by Fan, Bin, Le, Kha, Manyak, Erika, Liu, Hua, Prahl, Malia, Bowden, Chris J, Biller, Scott, Agresta, Sam, Yang, Hua

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    1288. Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections

    1288. Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial I... by Talley, Angela, Thurston, Archie, Moore, Grayson, Satterfield, Myriah M, Manyak, Erika L, Kumar, Vipul, Stokes, Suzanne, Dane, Aaron, Melnick, David

    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Abstract 1836: RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in patient tumors

    Abstract 1836: RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in patient tumors by Kuplast-Barr, Kristy, Johnson, Melissa L., Patel, Manish R., Yap, Timothy A., Falchook, Gerald S., LoRusso, Patricia, Abo, Ryan, Liu, Chang, Manyak, Erika L., Cleary, Lisa, Bozon, Viviana, Parasuraman, Sudha, Keilhack, Heike, McEachern, Kristen

    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

    Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial by Gao, Yue, Fan, Bin, Le, Kha, Manyak, Erika, Yang, Hua, Yen, Katherine, Agresta, Sam, Attar, Eyal C., Chen, Jian, Xu, Qiang, Tosolini, Alessandra, Mei, Jay M., Thakurta, Anjan, Knight, Robert D., Li, Yan

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: